Specifically inhibits S-nitrosylation of DNA methyltransferase 3B (DNMT3B) at low concentrations, IC50100 nM, without affecting its enzymatic activity. Treatment with DBIC prevents nitric oxide-induced conversion of human colonic adenoma to adenocarcinoma in vitro. Treatment with DBIC strongly attenuates tumor development in a mouse model of carcinogenesis triggered by inflammation-induced NO production. DNMT3B-mediated DNA methylation is regulated by S-nitrosylaton and DBIC represents a new useful tool for studying this system.1 A negative control compound, DBIC-neg2 (Cat 10-5162) is also available.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
